Therapy Strategies for Late-life Depression: A Review. Issue 1 (5th January 2023)

• Record Type: Journal Article
• Authors: Piel, Carla; Quante, Arnim
• Is Part Of: Journal of psychiatric practice. Volume 29:Issue 1(2023)
• Page Start: 15
• Page End: 30
• Publication Date: 2023-01-05
• Subjects: late-life depression -- pharmacotherapy -- antidepressants -- selective serotonin reuptake inhibitors -- psychotherapy -- treatment resistance -- electroconvulsive therapy (ECT) -- lithium; Psychiatry -- Periodicals; Psychotherapy -- Periodicals; Mental health services -- Periodicals; 616.8917
• DOI: 10.1097/PRA.0000000000000678
• Languages: English
• ISSNs: 1527-4160

Abstract

Abstract : Background: Depression in the elderly requires different treatment options because therapies that are commonly used for depression in younger patients show different effects later in life. Treatment options for late-life depression (LLD) are summarized in this article. Methods: A literature search in Medline/PubMed performed in June 2020 identified 83 relevant studies. Results: Pharmacotherapy with selective serotonin reuptake inhibitors can be an effective first-line treatment in LLD, but >50% of elderly patients do not adequately respond. Switching to other selective serotonin reuptake inhibitors or augmenting with mood stabilizers or antipsychotics is often effective in achieving a therapeutic benefit. Severely depressed patients with a high risk of suicidal behavior can be treated with electroconvulsive therapy. Psychotherapy provides a measurable benefit alone and when combined with medication. Limitations: LLD remains an underrepresented domain in research. Paucity of data concerning the effect of specific therapies for LLD, heterogeneity in the quality of study designs, overinterpretation of results from meta-analyses, and discrepancies between study results and guideline recommendations were often noted. Conclusions: Treating LLD is complex, but there are several treatment options with good efficacy and tolerability. Some novel pharmaceuticals also show promise as potential antidepressants, but evidence for their efficacy and safety is still limited and based on only a few trials conducted to date.